GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.
In a strategic move to enhance their immunology portfolio, GSK has announced an agreement to acquire experimental therapy ...
GSK (GSK) plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire ...
GlobalData on MSN6d
GSK to acquire Chimagen’s CMG1A46 for autoimmune diseaseGlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell-driven autoimmune diseases, for $300m upfront.
GSK inks agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline: London, UK Thursday, October 31, 2024, 10:00 Hrs [IST] GSK plc and Chimagen Bioscien ...
Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.
Astra saw £14.4bn wiped off its value after Chinese media said dozens of managers were implicated in a scandal.
GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback